<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04067310</url>
  </required_header>
  <id_info>
    <org_study_id>PROT</org_study_id>
    <nct_id>NCT04067310</nct_id>
  </id_info>
  <brief_title>Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis.</brief_title>
  <official_title>Randomized, Open-label Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis in Patients With Anal and Rectal Canal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancer, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancer, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, single-institution trial designed to evaluate the&#xD;
      effectiveness of a spray skin protector in preventing moist desquamation caused by&#xD;
      radiotherapy treatment.&#xD;
&#xD;
      This technology, spray skin protection, depending on the manufacturer, is primarily intended&#xD;
      to prevent or reduce contact dermatitis. However, this study will be evaluated for use in&#xD;
      preventing mois desquamation caused by ionizing radiation. The comparing agent will be a&#xD;
      moisturizer containing in its composition calendula officinalis, agreed upon at the local&#xD;
      Institution of the study for use in the prevention of radiodermatitis. As secondary&#xD;
      objectives: describe adverse events, diarrhea, pain and pruritus.&#xD;
&#xD;
      The study will be conducted at the radiotherapy outpatient clinic of the Cancer Hospital I&#xD;
      (HCI) of National Cancer Institute (INCA) in Brazil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypotheses are:&#xD;
&#xD;
      Null (Ho): The incidence of moist desquamation with the spray skin protector is greater than&#xD;
      or equal to the incidence of moist desquamation in the control group.&#xD;
&#xD;
      Alternative (H1): The incidence of moist desquamation with the spray skin protector is lower&#xD;
      than the incidence of moist desquamation in the control group.&#xD;
&#xD;
      The skin evaluation of the participants will be weekly, with blinding of this professional.&#xD;
      For the assessment of secondary objectives, adverse events will be applied to the diarrhea&#xD;
      assessment scales of Radiation Therapy Oncology Group (RTOG) and CTCAE version 5.0; for&#xD;
      pruritus the CTCAE scale; for pain the Analog Visual Scale (VAS) and the burning or burning&#xD;
      sensation will only be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">June 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>After signing the Informed Consent Form, randomization will be carried out in two groups: Experimental, which will use the skin protector in spray and control, which will use the moisturizer Dnativ Revita with calendula officinalis in its composition.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinding will be in skin evaluation and statistical analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Moist desquamation incidence</measure>
    <time_frame>from the first day of radiotherapy up to eight weeks</time_frame>
    <description>Moist desquamation incidence after the beginning of radiotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>from the first day of radiotherapy up to eight weeks</time_frame>
    <description>Occurrence of adverse events after the beginning of radiotherapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Radiodermatitis</condition>
  <condition>Injury, Radiation</condition>
  <arm_group>
    <arm_group_label>Group Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who will use the spray skin protector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who will use moisturizer containing in its composition calendula officinalis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spray skin protector</intervention_name>
    <description>Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.</description>
    <arm_group_label>Group Experimental</arm_group_label>
    <other_name>barrier film to prevent radiodermatitis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>moisturizer containing in its composition calendula officinalis</intervention_name>
    <description>Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.</description>
    <arm_group_label>Group control</arm_group_label>
    <other_name>conventional treatment to prevent radiodermatitis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: patients with curative indication and conventional linear accelerator&#xD;
        treatment planning; no previous history of radiotherapy in the same field / place of&#xD;
        treatment.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:patients with pre-existing irradiated dermatitis, which makes skin&#xD;
        assessment difficult; previous report of allergic reaction to any of the products used in&#xD;
        the research.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabiana Simões, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Rio de Janeiro (UFRJ)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Co-orientador, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Rio de Janeiro (UFRJ)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beatriz Co-orientadora, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal Fluminense (UFF)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INCA Research Center</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20231092</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancer, Brazil</investigator_affiliation>
    <investigator_full_name>Fabiana Verdan Simões</investigator_full_name>
    <investigator_title>Principal Research Nurse</investigator_title>
  </responsible_party>
  <keyword>barrier film</keyword>
  <keyword>spray skin protection</keyword>
  <keyword>liquid-film</keyword>
  <keyword>barrier product</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiodermatitis</mesh_term>
    <mesh_term>Radiation Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

